HSD? Moort

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jian Ni et al.

Application Number: 09/227,854 Group Art Unit: 1646

Filed: January 11, 1999 Examiner: G. Draper

Title: HUMAN CHEMOTACTIC CYTOKINE I Attny. Docket No. PF210D1

## INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.56

Assistant Commissioner for Patents Washington, D.C. 20231

SIR:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the cited references listed on the attached form PTO 1449.

Copies of references A1-A2 and C1-C18 were submitted by Applicants or cited by the Examiner in connection with U. S. Patent Application Serial No. 08/761,289, filed December 1, 1996, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of United States Patent Application Serial No. 08/761,289 for copies of references A1-A2 and C1-C18. A copy of references B1 and C19-C27 and C30-C40 is enclosed; a copy of references C28-C29 is forthcoming.

Applicants also wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding cDNA clones of the above-captioned application is related to:

(a) SEQ ID NO: 57 in copending U.S. Patent Application Serial No. 08/196,482.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Science, Inc., deposit account no. 08-3425. A copy of this sheet is enclosed.

Respectfully submitted,

Date: \_\_\_\_\_\_\_\_

Michelle S. Marks Attorney for Applicant (Reg. No. 41,971)

Human Genome Sciences, Inc.

9410 Key West Avenue Rockville, MD 20850 Phone (301) 610-5761

MSM/mbp

